Biotechnology The lipid-modifying agents market, which had seen a dramatic decline over the past decade, is now set for a spectacular revival, driven by the innovating therapies Leqvio (inclisiran) from Swiss pharma giant Novartis and Repatha (evolocumab) from US biotech Amgen. 5 July 2024